TY - JOUR
T1 - Effective use of weight-based enoxaparin for deep vein thrombosis chemoprophylaxis in patients with traumatic brain injury
AU - Taylor, Ashley
AU - Martinez-Quinones, Patricia
AU - Huang, Ellen
AU - Robinson, Tim
AU - White, Cassandra Q.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Enoxaparin is the recommended agent for deep vein thrombosis (DVT) chemoprophylaxis in trauma patients. Current literature suggests weight-based dosing is superior to standard dosing for adequate chemoprophylaxis. Literature regarding the use of weight-based enoxaparin in the setting of traumatic brain injury (TBI) however is limited. Methods: A retrospective analysis of adult trauma patients admitted between January 1, 2018 to February 28, 2019 was performed. Sixty-six patients with TBI receiving weight-based enoxaparin met inclusion criteria. Incidence of intracranial hemorrhage (ICH) expansion was the primary endpoint. Newly diagnosed venous thromboembolism (VTE) and death were secondary endpoints. Results: Two patients, out of sixty-six, had progression of their TBI requiring surgical intervention. Newly diagnosed VTE occurred in one patient. No deaths were due to ICH expansion or VTE. Conclusions: Use of weight-based enoxaparin dosing in the setting of TBI shows promise without an increased incidence of ICH expansion when compared to other studies. Level of Evidence and Study Type: Level IV, Therapeutic.
AB - Background: Enoxaparin is the recommended agent for deep vein thrombosis (DVT) chemoprophylaxis in trauma patients. Current literature suggests weight-based dosing is superior to standard dosing for adequate chemoprophylaxis. Literature regarding the use of weight-based enoxaparin in the setting of traumatic brain injury (TBI) however is limited. Methods: A retrospective analysis of adult trauma patients admitted between January 1, 2018 to February 28, 2019 was performed. Sixty-six patients with TBI receiving weight-based enoxaparin met inclusion criteria. Incidence of intracranial hemorrhage (ICH) expansion was the primary endpoint. Newly diagnosed venous thromboembolism (VTE) and death were secondary endpoints. Results: Two patients, out of sixty-six, had progression of their TBI requiring surgical intervention. Newly diagnosed VTE occurred in one patient. No deaths were due to ICH expansion or VTE. Conclusions: Use of weight-based enoxaparin dosing in the setting of TBI shows promise without an increased incidence of ICH expansion when compared to other studies. Level of Evidence and Study Type: Level IV, Therapeutic.
KW - Anti-factor xa
KW - Chemoprophylaxis
KW - Traumatic brain injury
KW - Venous thromboembolism
KW - Weight-based enoxaparin
UR - http://www.scopus.com/inward/record.url?scp=85111677378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111677378&partnerID=8YFLogxK
U2 - 10.1016/j.amjsurg.2021.07.030
DO - 10.1016/j.amjsurg.2021.07.030
M3 - Article
C2 - 34340862
AN - SCOPUS:85111677378
SN - 0002-9610
VL - 223
SP - 146
EP - 150
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 1
ER -